Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
最近の投稿
- 1
High Court weighs Assenheim appeal over release of Feldstein interview raw footage - 2Countdown begins for long-awaited Artemis II moon mission
- 3Sexual violence part of 'everyday life' in parts of Sudan, charity says
- 4Good ways to respond if your kid brings home less-than-ideal grades
- 5Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- A Couple of Reasonable Guitars for 2024
- How food assistance programs can feed families and nourish their dignity
- The Best Internet based Courses for Expertise Improvement
- A NASA spacecraft orbiting Mars may be dead
- NASA’s Artemis II mission will take an astronaut crew around the Moon – a space policy expert describes the long road to launch
- Artemis II astronauts arrive at Florida launch site for first moon trip in 53 years
- Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- Find the Marvels of the World with These Travels
- German Court Rejects Bid To Force BMW and Mercedes-Benz To Stop Selling New Combustion-Engine Cars After 2030
